BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4069549)

  • 1. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
    Case DC; Porensky RS; Fanning JP
    Oncology; 1985; 42(6):350-3. PubMed ID: 4069549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
    Kempin S; Lee BJ; Thaler HT; Koziner B; Hecht S; Gee T; Arlin Z; Little C; Straus D; Reich L; Phillips E; Al-Mondhiry H; Dowling M; Mayer K; Clarkson B
    Blood; 1982 Nov; 60(5):1110-21. PubMed ID: 6751436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
    Case DC; Boyd M; Hayes DM; Dorsk BM
    Oncology; 1988; 45(6):417-20. PubMed ID: 3054672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
    Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
    Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.
    Montserrat E; Alcalá A; Parody R; Domingo A; García-Conde J; Bueno J; Ferrán C; Sanz MA; Giralt M; Rubio D
    Cancer; 1985 Nov; 56(10):2369-75. PubMed ID: 3899346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of M-2 protocol with COP in patients with nodular lymphoma.
    Case DC
    Oncology; 1984; 41(3):159-63. PubMed ID: 6547220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia.
    Rai KR; Sawitsky A; Jagathambal K; Gartenhaus W; Phillips E
    Med Clin North Am; 1984 May; 68(3):697-711. PubMed ID: 6379339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results with the use of the M-2 protocol in plasmacytoma].
    Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
    Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
    Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
    Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia.
    Keating MJ; Scouros M; Murphy S; Kantarjian H; Hester J; McCredie KB; Hersh EM; Freireich EJ
    Leukemia; 1988 Mar; 2(3):157-64. PubMed ID: 3347094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.
    Raphael B; Andersen JW; Silber R; Oken M; Moore D; Bennett J; Bonner H; Hahn R; Knospe WH; Mazza J
    J Clin Oncol; 1991 May; 9(5):770-6. PubMed ID: 2016618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.